Australien - Englisch - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; povidone; macrogol 4000; magnesium stearate; lactose monohydrate; titanium dioxide; silicon dioxide; poloxamer; hypromellose - adults: roxithromycin sandoz is indicated for the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible microorganisms. upper respiratory tract infection: acute pharyngitis, tonsilitis and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. children: roxithromycin sandoz 150mg tablets are indicated for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible microorganisms. acute pharyngitis. acute tonsilitis. impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be inititiated before results of these tests are known; once results become available, appropriate therapy should be continued.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - erythromycin ethyl succinate, quantity: 482.04 mg (equivalent: erythromycin, qty 400 mg) - tablet, film coated - excipient ingredients: sodium starch glycollate; povidone; maize starch; sorbic acid; calcium hydrogen phosphate; purified talc; magnesium stearate; titanium dioxide; iron oxide red; xanthan gum; polyvinyl alcohol; lecithin - streptococcus pyogenes (group a beta-haemolytic streptococcus). upper and lower respiratory tract, skin and skin structure infections of mild to moderate severity. when oral medication is given, patient must comply with the prescribed regimen. therapeutic dose should be administered for at least 10 days. alpha haemolytic streptococci (viridans group). no controlled clinical efficacy trials have been conducted, however oral erythromycin has been suggested by the american heart association and the american dental association for use in bacterial endocarditis prophylaxis prior to dental/surgical procedures of the upper respiratory tract in penicillin-hypersensitive patients with a history of rheumatic, congenital or other acquired valvular heart disease. erythromycin is unsuitable prior to genitourinary or gastrointestinal tract surgery. staphylococcus aureus. acute infections of skin and skin structure of mild to moderate severity. bacterial resistance may emerge during treatment, hence cultures and sensitivity tests should be performed. streptococcus pneumoniae (diplococcus pneumoniae). upper (e.g. otitis media, pharyngitis) and lower respiratory tract infections (e.g. pneumonia) of mild to moderate degree. mycoplasma pneumoniae (eaton agent, pplo). for respiratory infections due to this organism. haemophilus influenzae. for upper respiratory tract infections of mild to moderate severity. not all strains are susceptible at the erythromycin concentrations normally achieved. chlamydia trachomatis and ureaplasma urealyticum. these organisms are sensitive to erythromycin; clinical studies have demonstrated erythromycin's efficacy in nongonococcal urethritis due to these organisms. a minimum of 10 days therapy is required. chlamydia trachomatis infection (excluding nongonococcal urethritis). erythromycin has shown to be effective in treating trachoma or inclusion body conjunctivitis, acute inclusion conjunctivitis of the newborn (inclusion blennorrhoea) and pneumonia in infants caused by chlamydia trachomatis. treponema pallidum. erythromycin is an alternative drug in treating primary syphilis in patients allergic to penicillins. spinal fluid examinations should be done before treatment and as part of follow-up post therapy. neisseria gonorrhoeae. erythromycin lactobionate for injection in conjunction with oral erythromycin ethylsuccinate, as an alternative treatment for acute uncomplicated gonorrhoea in female patients with penicillin hypersensitivity. before treatment, patients who are suspected of also having syphilis should be evaluated including a microscopic examination for t. pallidum (by immunofluorescence or darkfield) before receiving erythromycin, and monthly serologic tests should be performed for a minimum of 4 months. corynebacterium diphtheriae, c. minutissimum and c. (propionibacterium) acnes. as an adjunct to diphtheria antitoxin, to prevent establishment of carriers, and to eradicate the organism in carriers; in the treatment of erythrasma; adjunctive therapy of moderate to severe acne. bordetella pertussis. for early elimination of the causative organism from the nasopharynx. therapeutic doses should be continued for at least 10 days. the clinical course of the disease is not altered. clostridium tetani. in vitro, clostridium tetani is sensitive to erythromycin. erythromycin may be used prophylatically in penicillin-hypersensitive persons for 5 days. as the value of antibiotic prophylaxis in tetanus is not unequivocally established, wounds should be regularly examined. legionnaires' disease. although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating legionnaires' disease. campylobacter fetus (subspecies) jejuni, listeria monocytogenes. infections due to this organism when antibiotic therapy is indicated.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - lacosamide, quantity: 200 mg - tablet, film coated - excipient ingredients: hyprolose; crospovidone; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350; indigo carmine aluminium lake - vimpat (lacosamide) tablets and oral solution are indicated as:,? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.,? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older.,? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - lacosamide, quantity: 150 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; crospovidone; magnesium stearate; colloidal anhydrous silica; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black - vimpat (lacosamide) tablets and oral solution are indicated as:,? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.,? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older.,? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - lacosamide, quantity: 100 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hyprolose; microcrystalline cellulose; crospovidone; magnesium stearate; titanium dioxide; purified talc; iron oxide yellow; polyvinyl alcohol; macrogol 3350 - vimpat (lacosamide) tablets and oral solution are indicated as:,? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.,? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older.,? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - lacosamide, quantity: 50 mg - tablet, film coated - excipient ingredients: hyprolose; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; crospovidone; titanium dioxide; purified talc; iron oxide red; polyvinyl alcohol; macrogol 3350; iron oxide black; indigo carmine aluminium lake - vimpat (lacosamide) tablets and oral solution are indicated as:,? monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older.,? add-on therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy aged 4 years and older.,? add-on therapy in the treatment of primary generalised tonic-clonic seizures in patients with idiopathic generalised epilepsy aged 4 years and older.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quinapril hydrochloride, quantity: 21.664 mg (equivalent: quinapril, qty 20 mg) - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; povidone; crospovidone; magnesium carbonate hydrate; calcium sulfate dihydrate; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quinapril hydrochloride, quantity: 10.832 mg (equivalent: quinapril, qty 10 mg) - tablet, film coated - excipient ingredients: calcium sulfate dihydrate; magnesium stearate; magnesium carbonate hydrate; colloidal anhydrous silica; crospovidone; povidone; titanium dioxide; purified talc; iron oxide yellow; xanthan gum; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - quinapril hydrochloride, quantity: 5.416 mg (equivalent: quinapril, qty 5 mg) - tablet, film coated - excipient ingredients: magnesium stearate; magnesium carbonate hydrate; calcium sulfate dihydrate; povidone; crospovidone; colloidal anhydrous silica; titanium dioxide; xanthan gum; iron oxide yellow; purified talc; polyvinyl alcohol; lecithin - hypertension: quinapril hydrochloride tablets are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. sufficient data have not been provided to support the use of quinapril tablets in renovascular hypertension. congestive heart failure: quinapril hydrochloride tablets are indicated as an adjunctive treatment of mild to moderate congestive heart failure when given concomitantly with a diuretic and/or cardiac glycoside.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - sumatriptan succinate, quantity: 139.98 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; microcrystalline cellulose; lactose monohydrate; croscarmellose sodium; titanium dioxide - sumatran tablets are indicated for the acute relief of migraine attacks with or without aura.